A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 1, 2007

Once-Daily Viramune Strikes Out

by Tim Horn

For several years, Boehringer Ingelheim and independent researchers have been looking into the possibility of once-daily Viramune® (nevirapine) dosing, to help simplify its use in the treatment of HIV. However, new research presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) suggests that the approved twice-daily schedule will remain the necessary dosing option, especially for those starting therapy with high viral loads, based on a significantly greater number of virologic failures seen in a French study comparing the two dosing schedules.

The DAUFIN study randomized 71 HIV-positive patients to one of two treatment groups.  In the first group, 36 patients took once-daily Viramune (400mg), Viread® (tenofovir; 245 mg), and Epivir® (lamivudine, 300 mg). In the second group, 35 patients took twice-daily Viramune (200 mg) and Combivir® (zidovudine plus lamivudine).  All patients were treatment-naïve – new to treatment at the start of the study – and the men had to have CD4 counts below 350, whereas the women had to have CD4 counts below 250 (to reduce the risk of Viramune-related hypersensitivity). 

The average viral loads at study entry were 71,500 in the once-daily group and 80,282 in the twice-daily group. Pre-treatment CD4 counts average 208 cells in both groups. 

The study began in May 2005, with a planned target enrollment of 250 patients. However, by May of 2006, early virologic failure was documented in seven patients – all in the once-daily group – leading to early termination of the study.  The data presented at CROI reflected results for 71 patients enrolled in the trial before it was discontinued.

In total, eight individuals – again, all in the once-daily group – experienced early virologic failure, defined as a viral load that failed to drop more than 2 log by week 12 or a greater than 1 log rebound in viral load by week 12. Two additional patients experienced virologic rebound later in the study, one in each study group.

It was not initially clear why patients in the once-daily group were much more likely to experience virologic failure compared to those in the twice-daily group.  Trough concentrations of Viramune – a measure of the drug in the blood – were somewhat lower in the once-daily group, but not significantly so. 

Two factors that did seem to play a role in early virologic failure were high viral loads and low CD4 counts at the time of study entry. The average pre-treatment viral load among those who maintained virologic control was 51,189. Among those who experienced virologic failure, the average pre-treatment viral load was 262,747. As for pre-treatment CD4 cells, the average count among those who continued to respond well to treatment was 223, vs. an average pre-treatment count of 110 among those who experienced virologic failure. These differences were statistically significant.

While discontinuation due to side effects was slightly more common among individuals in the twice-daily group compared to the once-daily group, the difference was not statistically significant.


Rey D, Schmitt MP, Hoizey G, et al. Early virologic non-response to once daily combination of lamivudine, tenofovir, and nevirapine in ART-naive HIV-infected patients: preliminary results of the DAUFIN study [Abstract 503]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007.

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.